238 related articles for article (PubMed ID: 20190366)
1. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
Takami M; Shimada H
Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
[TBL] [Abstract][Full Text] [Related]
2. [Bone metabolic marker for osteoporosis].
Shidara K; Inaba M
Nihon Rinsho; 2009 May; 67(5):927-31. PubMed ID: 19432111
[TBL] [Abstract][Full Text] [Related]
3. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
4. [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
Saito M
Clin Calcium; 2010 Mar; 20(3):345-54. PubMed ID: 20190364
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene on bone metabolism in postmenopausal women on chronic hemodialysis.
Nagatoya K; Nishimoto K; Shibahara N; Takahashi T; Kanehara H; Ueno N; Yasuda H; Okada S; Ueda H; Hirai K; Inoue T;
Clin Exp Nephrol; 2015 Oct; 19(5):939-46. PubMed ID: 25504368
[TBL] [Abstract][Full Text] [Related]
6. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
7. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Kobayashi H; Hamaya E
Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
[No Abstract] [Full Text] [Related]
8. Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.
Ohta H; Uemura Y; Sone T; Tanaka S; Soen S; Mori S; Hagino H; Fukunaga M; Nakamura T; Orimo H; Shiraki M;
Calcif Tissue Int; 2023 Apr; 112(4):430-439. PubMed ID: 36707436
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
Chung YE; Lee SH; Lee SY; Kim SY; Kim HH; Mirza FS; Lee SK; Lorenzo JA; Kim GS; Koh JM
Osteoporos Int; 2012 Apr; 23(4):1235-43. PubMed ID: 21660558
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
11. [Clinical usefulness of bone turnover markers with the treatment of osteoporosis].
Miura M
Clin Calcium; 2014 Mar; 24(3):367-76. PubMed ID: 24576933
[TBL] [Abstract][Full Text] [Related]
12. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
[TBL] [Abstract][Full Text] [Related]
13. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic imaging of treatment in osteoporosis: SERM].
Takada J; Iba K; Yamashita T
Clin Calcium; 2011 Jul; 21(7):1047-55. PubMed ID: 21719986
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
Muchmore DB
Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
[TBL] [Abstract][Full Text] [Related]
16. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
17. [Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].
Ohta H
Nihon Rinsho; 2009 May; 67(5):960-6. PubMed ID: 19432117
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of bone quality. Bone quality and osteoporosis treatment].
Mashiba T
Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
[TBL] [Abstract][Full Text] [Related]
19. [New approved markers of bone turnover for osteoporosis in Japan].
Miki T; Masaki H
Clin Calcium; 2012 Jun; 22(6):877-83. PubMed ID: 22653028
[TBL] [Abstract][Full Text] [Related]
20. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
